A. Stephens

发表

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Edward S. Kim, Robin L. Jones, S. Lippman, 2014, Clinical Cancer Research.

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.

I. Macpherson, R. Gedrich, G. Simon, 2013, European journal of cancer.

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma.

D. Tan, S. Kaye, P. Schöffski, 2010 .

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

C. Rudin, S. Gadgeel, R. Gedrich, 2016, Clinical Cancer Research.

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

G. Demetri, S. Gwyther, M. Leach, 2013, Clinical Cancer Research.

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.

Edward S. Kim, Robin L. Jones, S. Lippman, 2010 .

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

T. Choueiri, E. Baudin, M. Fassnacht, 2015, The Lancet. Oncology.

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

I. Puzanov, E. Chan, C. Lindsay, 2010 .

Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors.

I. Puzanov, E. Chan, C. Lindsay, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

J. Berlin, I. Puzanov, E. Chan, 2014, Clinical Cancer Research.

Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors.

S. Lippman, S. Kaye, C. Carden, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

C. Rudin, S. Gadgeel, R. Gedrich, 2016, Clinical Cancer Research.

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Edward S. Kim, Robin L. Jones, S. Lippman, 2014, Clinical Cancer Research.